JMP Securities lowered the firm’s price target on AMN Healthcare to $66 from $75 and keeps an Outperform rating on the shares. JMP remains constructive on shares following the quarterly results, given AMN’s diversified platform and the firm’s thesis that AMN can begin to deliver sequential quarterly revenue growth in 2025, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMN: